Gout FocusRheum

ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.

CPPD is notoriously difficult to diagnose due to its diverse presentations & uncertain etiology. Recent advances have helped rheumatologists better understand its risk factors, classify, diagnose & treat the condition.

Understanding the role of NLRP3 inflammasome activation in gout flares points to potential of NLRP3 inflammasome inhibitors as a new treatment option.

Initial findings from a phase 2b clinical trial demonstrate the safety and efficacy of three different daily doses of SAP-001 to lower the serum urate levels of patients with refractory gout.

At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.

In a new-patient consultation for joint pain, you see a 75-year-old man with a history of dementia, stage 3a chronic kidney disease (CKD) and nephrolithiasis. He has a uric acid level of 7.5 mg/dL. His medication list includes 300 mg daily allopurinol. What is NOT an indication for allopurinol? CKD-FIX Elevated serum urate levels are…

Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2024.

Experts addressed how education and follow-up for patients with gout can improve disease management and highlighted the need for a better construction of gout remission.

Dr. Khaled Elsaid discussed synovial macrophages/monocytes and monosodium urate crystal interactions at a session during ACR Convergence, exploring potential new gout pharmacology targets via the lubricin/CD44/protein phosphatase 2A (PP2A) pathway.

An ACR Convergence 2024 session will discuss strategies to educate patients about their disease and review the progress toward the concept of remission in gout to better guide physicians.